No significant weaknesses identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ACADACADIA Pharmaceuticals Inc. | 4.54B | 26.86 | 19.75 | 31.85% | 24.94% | 28.47% | 3.46% | 0.07 |
| JAZZJazz Pharmaceuticals plc | 10.38B | 170.81 | 19.75 | 6.12% | -8.86% | -9.31% | 12.99% | 1.51 |
| CPRXCatalyst Pharmaceuticals, Inc. | 2.85B | 23.17 | 17.69 | 23.49% | 37.63% | 23.64% | 8.4% | 0.00 |
| HRMYHarmony Biosciences Holdings, Inc. | 2.08B | 36.04 | 14.36 | 22.8% | 22.48% | 22.23% | 10.53% | 0.28 |
| ALKSAlkermes plc | 5.06B | 30.62 | 14.11 | -6.36% | 22.27% | 19.55% | 8.02% | 0.05 |
| PRTCPureTech Health plc | 458.47M | 18.97 | 9.49 | 44.98% | -495.91% | -8.53% | 0.05 | |
| LBRXLB Pharmaceuticals Inc Common Stock | 489.79M | 19.36 | -1.09 | |||||
| NMRANeumora Therapeutics, Inc. Common Stock | 365.37M | 2.15 | -1.41 | -178.79% | 0.01 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 6M | 159.74M | 305.44M | 437.86M | 582.02M | 714.73M |
| Revenue Growth % | - | - | 25.65% | 0.91% | 0.43% | 0.33% | 0.23% |
| Cost of Goods Sold | 184K | 1.58M | 27.74M | 55.52M | 83.48M | 121.24M | 156.81M |
| COGS % of Revenue | - | 0.26% | 0.17% | 0.18% | 0.19% | 0.21% | 0.22% |
| Gross Profit | -184K | 4.42M | 132M | 249.92M | 354.37M | 460.79M | 557.92M |
| Gross Margin % | - | 0.74% | 0.83% | 0.82% | 0.81% | 0.79% | 0.78% |
| Gross Profit Growth % | - | 25.01% | 28.88% | 0.89% | 0.42% | 0.3% | 0.21% |
| Operating Expenses | 41.44M | 150.32M | 115.02M | 162.39M | 234.19M | 268.76M | 367.09M |
| OpEx % of Revenue | - | 25.07% | 0.72% | 0.53% | 0.53% | 0.46% | 0.51% |
| Selling, General & Admin | 29.07M | 80.73M | 95.57M | 132.03M | 163.3M | 192.69M | 221.27M |
| SG&A % of Revenue | - | 13.47% | 0.6% | 0.43% | 0.37% | 0.33% | 0.31% |
| Research & Development | 12.37M | 69.59M | 19.45M | 30.37M | 70.89M | 76.06M | 145.82M |
| R&D % of Revenue | - | 11.61% | 0.12% | 0.1% | 0.16% | 0.13% | 0.2% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -41.44M | -145.9M | 16.99M | 87.53M | 120.19M | 192.03M | 190.83M |
| Operating Margin % | - | -24.34% | 0.11% | 0.29% | 0.27% | 0.33% | 0.27% |
| Operating Income Growth % | - | -2.52% | 1.12% | 4.15% | 0.37% | 0.6% | -0.01% |
| EBITDA | -41.26M | -142.69M | 27.22M | 106.37M | 143.57M | 216.39M | 214.94M |
| EBITDA Margin % | - | -23.8% | 0.17% | 0.35% | 0.33% | 0.37% | 0.3% |
| EBITDA Growth % | - | -2.46% | 1.19% | 2.91% | 0.35% | 0.51% | -0.01% |
| D&A (Non-Cash Add-back) | 184K | 3.21M | 10.24M | 18.84M | 23.39M | 24.36M | 24.11M |
| EBIT | -41.44M | -145.9M | -8.72M | 61.62M | 123.48M | 197.15M | 209.3M |
| Net Interest Income | 0 | -6.07M | -28.22M | -23.97M | -15.67M | -9.03M | 1.05M |
| Interest Income | 0 | 0 | 0 | 224K | 3.13M | 14.73M | 18.54M |
| Interest Expense | 0 | 6.07M | 28.22M | 24.19M | 18.8M | 23.76M | 17.5M |
| Other Income/Expense | 1.54M | -6.07M | -53.93M | -50.1M | -15.5M | -18.63M | 978K |
| Pretax Income | -39.9M | -151.98M | -36.94M | 37.43M | 104.69M | 173.4M | 191.8M |
| Pretax Margin % | - | -25.35% | -0.23% | 0.12% | 0.24% | 0.3% | 0.27% |
| Income Tax | 0 | 0 | 0 | 2.83M | -76.78M | 44.54M | 46.31M |
| Effective Tax Rate % | 1% | 1% | 1% | 0.92% | 1.73% | 0.74% | 0.76% |
| Net Income | -39.9M | -151.98M | -36.94M | 34.6M | 181.47M | 128.85M | 145.49M |
| Net Margin % | - | -25.35% | -0.23% | 0.11% | 0.41% | 0.22% | 0.2% |
| Net Income Growth % | - | -2.81% | 0.76% | 1.94% | 4.25% | -0.29% | 0.13% |
| Net Income (Continuing) | -39.9M | -151.98M | -36.94M | 34.6M | 181.47M | 128.85M | 145.49M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.42 | -2.94 | -1.10 | 0.58 | 2.97 | 2.13 | 2.51 |
| EPS Growth % | - | -1.07% | 0.63% | 1.53% | 4.12% | -0.28% | 0.18% |
| EPS (Basic) | -1.42 | -2.94 | -1.12 | 0.60 | 3.07 | 2.17 | 2.56 |
| Diluted Shares Outstanding | 49.24M | 63.68M | 57.85M | 59.21M | 61.1M | 60.37M | 57.87M |
| Basic Shares Outstanding | 49.24M | 63.68M | 56.89M | 57.53M | 59.17M | 59.47M | 56.88M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 86.68M | 31.5M | 262.89M | 284.44M | 400.29M | 451.07M | 579.25M |
| Cash & Short-Term Investments | 83.52M | 24.46M | 228.63M | 234.31M | 323.12M | 353.46M | 467.19M |
| Cash Only | 83.52M | 24.46M | 228.63M | 234.31M | 243.78M | 311.66M | 453M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 79.33M | 41.8M | 14.19M |
| Accounts Receivable | 0 | 4.25M | 22.18M | 34.84M | 54.74M | 74.14M | 83.03M |
| Days Sales Outstanding | - | 259.06 | 50.67 | 41.64 | 45.63 | 46.49 | 42.4 |
| Inventory | 0 | 1.09M | 3.82M | 4.43M | 4.3M | 5.36M | 7.2M |
| Days Inventory Outstanding | - | 251.82 | 50.31 | 29.14 | 18.79 | 16.15 | 16.75 |
| Other Current Assets | 2.46M | 261K | 1.3M | 3.22M | 8.79M | 5.54M | 8.12M |
| Total Non-Current Assets | 2.6M | 75.21M | 164.18M | 149M | 273.58M | 360.38M | 419.95M |
| Property, Plant & Equipment | 1.58M | 1.33M | 938K | 4.12M | 573K | 371K | 3.38M |
| Fixed Asset Turnover | - | 4.51x | 170.30x | 74.17x | 764.14x | 1568.79x | 211.52x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 72.19M | 162.34M | 143.92M | 160.95M | 137.11M | 113.26M |
| Long-Term Investments | 500K | 0 | 0 | 0 | 22.57M | 72.17M | 108.87M |
| Other Non-Current Assets | 522K | 1.69M | 902K | 967K | 3.55M | 6.57M | 194.43M |
| Total Assets | 89.28M | 106.7M | 427.07M | 433.44M | 673.87M | 811.45M | 999.2M |
| Asset Turnover | - | 0.06x | 0.37x | 0.70x | 0.65x | 0.72x | 0.72x |
| Asset Growth % | - | 0.2% | 3% | 0.01% | 0.55% | 0.2% | 0.23% |
| Total Current Liabilities | 7.23M | 19.89M | 134.54M | 53.77M | 78.88M | 163.78M | 175.08M |
| Accounts Payable | 1.46M | 6.36M | 2.56M | 1M | 3.79M | 17.73M | 13.74M |
| Days Payables Outstanding | 2.9K | 1.47K | 33.63 | 6.58 | 16.55 | 53.38 | 31.99 |
| Short-Term Debt | 0 | 0 | 0 | 2M | 2M | 15M | 16.25M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 313K | 753K | 100.31M | 1 | 1.62M | 107.3M | 4.35M |
| Current Ratio | 11.99x | 1.58x | 1.95x | 5.29x | 5.07x | 2.75x | 3.31x |
| Quick Ratio | 11.99x | 1.53x | 1.93x | 5.21x | 5.02x | 2.72x | 3.27x |
| Cash Conversion Cycle | - | -961.15 | 67.34 | 64.19 | 47.87 | 9.26 | 27.17 |
| Total Non-Current Liabilities | 523K | 98.4M | 195.35M | 193.16M | 192.15M | 180.68M | 164.96M |
| Long-Term Debt | 324.2M | 97.95M | 194.25M | 189.98M | 189.65M | 178.57M | 163.02M |
| Capital Lease Obligations | 0 | 0 | 0 | 2.4M | 0 | 0 | 822K |
| Deferred Tax Liabilities | -324.46M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -323.68M | 450K | 1.1M | 777K | 2.5M | 2.11M | 1.13M |
| Total Liabilities | 7.75M | 118.29M | 329.89M | 246.94M | 271.03M | 344.46M | 340.05M |
| Total Debt | 324.2M | 97.95M | 194.25M | 195.74M | 191.65M | 193.57M | 181.41M |
| Net Debt | 240.68M | 73.49M | -34.38M | -38.56M | -52.14M | -118.09M | -271.6M |
| Debt / Equity | 3.98x | - | 2.00x | 1.05x | 0.48x | 0.41x | 0.28x |
| Debt / EBITDA | - | - | 7.14x | 1.84x | 1.33x | 0.89x | 0.84x |
| Net Debt / EBITDA | - | - | -1.26x | -0.36x | -0.36x | -0.55x | -1.26x |
| Interest Coverage | - | -24.03x | 0.60x | 3.62x | 6.39x | 8.08x | 10.91x |
| Total Equity | 81.53M | -11.59M | 97.18M | 186.51M | 402.84M | 466.99M | 659.15M |
| Equity Growth % | - | -1.14% | 9.39% | 0.92% | 1.16% | 0.16% | 0.41% |
| Book Value per Share | 1.66 | -0.18 | 1.68 | 3.15 | 6.59 | 7.74 | 11.39 |
| Total Shareholders' Equity | 81.53M | -11.59M | 97.18M | 186.51M | 402.84M | 466.99M | 659.15M |
| Common Stock | 1K | 0 | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | -242.67M | -422.86M | -488.19M | -453.6M | -272.13M | -143.28M | 2.22M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2K | 0 | 0 | 0 | -151K | 2K | 66K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -38.8M | -75.44M | -2.98M | 98.56M | 144.47M | 219.39M | 219.82M |
| Operating CF Margin % | - | -12.58% | -0.02% | 0.32% | 0.33% | 0.38% | 0.31% |
| Operating CF Growth % | - | -0.94% | 0.96% | 34.02% | 0.47% | 0.52% | 0% |
| Net Income | -39.9M | -151.98M | -36.94M | 34.6M | 181.47M | 128.85M | 145.49M |
| Depreciation & Amortization | 184K | 3.8M | 10.24M | 21.08M | 25.05M | 24.36M | 24.11M |
| Stock-Based Compensation | 1.08M | 9.91M | 4.69M | 16.11M | 26.91M | 31.7M | 42.6M |
| Deferred Taxes | 0 | 0 | 25.75M | 0 | 0 | -13.42M | -29.3M |
| Other Non-Cash Items | 2.06M | 59.44M | 4.91M | 24.59M | -82.06M | 12.85M | 44.23M |
| Working Capital Changes | -164K | 3.39M | -11.63M | 2.19M | -6.89M | 35.03M | -7.32M |
| Change in Receivables | 0 | -4.25M | -17.92M | -12.67M | -19.9M | -19.4M | -8.89M |
| Change in Inventory | 0 | -1.09M | -2.73M | -609K | 135K | -1.07M | -1.83M |
| Change in Payables | -610K | 0 | -3.8M | 0 | 0 | 8.95M | -5.38M |
| Cash from Investing | -1.34M | -127.15M | -2M | -100.3M | -141.83M | -46.44M | -67.48M |
| Capital Expenditures | -1.34M | -149K | -2M | -298K | -172K | -312K | -1.15M |
| CapEx % of Revenue | - | 0.02% | 0.01% | 0% | 0% | 0% | 0% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | -127M | 2M | -100M | -141.66M | 0 | -26.5M |
| Cash from Financing | 21.61M | 143.77M | 209.16M | 7.42M | 6.84M | -105.55M | -11M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | -185K | 43.77M | 129.93M | 7.92M | 8.84M | -3.79M | -2.5M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -40.14M | -75.58M | -4.99M | 98.26M | 144.29M | 219.07M | 218.67M |
| FCF Margin % | - | -12.61% | -0.03% | 0.32% | 0.33% | 0.38% | 0.31% |
| FCF Growth % | - | -0.88% | 0.93% | 20.7% | 0.47% | 0.52% | -0% |
| FCF per Share | -0.82 | -1.19 | -0.09 | 1.66 | 2.36 | 3.63 | 3.78 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.50x | 0.08x | 2.85x | 0.80x | 1.70x | 1.51x |
| Interest Paid | 0 | 4.23M | 0 | 19.83M | 16.36M | 20.05M | 17.32M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 48.23M | 79.64M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -48.94% | -434.57% | -86.32% | 24.39% | 61.58% | 29.63% | 25.84% |
| Return on Invested Capital (ROIC) | - | -56.98% | 20.43% | 62.3% | 36.15% | 41.17% | 38.87% |
| Gross Margin | - | 73.69% | 82.64% | 81.82% | 80.93% | 79.17% | 78.06% |
| Net Margin | - | -2535.06% | -23.13% | 11.33% | 41.44% | 22.14% | 20.36% |
| Debt / Equity | 3.98x | - | 2.00x | 1.05x | 0.48x | 0.41x | 0.28x |
| Interest Coverage | - | -24.03x | 0.60x | 3.62x | 6.39x | 8.08x | 10.91x |
| FCF Conversion | 0.97x | 0.50x | 0.08x | 2.85x | 0.80x | 1.70x | 1.51x |
| Revenue Growth | - | - | 2564.59% | 91.21% | 43.35% | 32.93% | 22.8% |
| 2022 | 2023 | |
|---|---|---|
| United States | 500M | 500M |
| United States Growth | - | 0.00% |
Harmony Biosciences Holdings, Inc. (HRMY) has a price-to-earnings (P/E) ratio of 14.4x. This may indicate the stock is undervalued or faces growth challenges.
Harmony Biosciences Holdings, Inc. (HRMY) reported $825.9M in revenue for fiscal year 2024.
Harmony Biosciences Holdings, Inc. (HRMY) grew revenue by 22.8% over the past year. This is strong growth.
Yes, Harmony Biosciences Holdings, Inc. (HRMY) is profitable, generating $185.7M in net income for fiscal year 2024 (20.4% net margin).
Harmony Biosciences Holdings, Inc. (HRMY) has a return on equity (ROE) of 25.8%. This is excellent, indicating efficient use of shareholder capital.
Harmony Biosciences Holdings, Inc. (HRMY) generated $296.9M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.